A leading US-headquartered, NASDAQ-listed, biopharmaceutical company targeting the global market, with a focus on China.
In the News
CASI's turnaround turns eastward; firm seeks to be Celgene of China
Read Article →
Antitumor activity, safety and predictive biomarker results of ENMD-2076 administered to patients with recurrent ovarian clear cell carcinoma (OCCC): A trial of the Princess Margaret Phase II Consortium
Senescence as a Mechanism of Resistance to Aurora Kinase Inhibition with ENMD-2076 in p53 mutated Triple-Negative Breast Cancer (TNBC) Models